A Multicenter Study to Evaluate the Pharmacokinetic Profile and Safety of TMC125 [Etravirine] Plus Tenofovir DF/Emtricitabine All Dosed Once Daily With and Without Darunavir (PREZISTA)/ Ritonavir Once Daily in Antiretroviral naive HIV-1 Infected Subjects.
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2010
At a glance
- Drugs Darunavir; Emtricitabine/tenofovir disoproxil fumarate; Etravirine; Ritonavir
- Indications HIV infections
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Tibotec Inc
- 31 Aug 2018 Biomarkers information updated
- 14 Apr 2010 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 14 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.